

Pedro Pedro Rosa Rosa-Neto

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/1972093/pedro-pedro-rosa-rosa-neto-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283
papers

8,289
citations

46
h-index

83
g-index

318
ext. papers

10,960
ext. citations

6.4
avg, IF

6
L-index

#	Paper	IF	Citations
283	Age- and gender-related differences in the cortical anatomical network. <i>Journal of Neuroscience</i> , 2009 , 29, 15684-93	6.6	500
282	Human brain white matter atlas: identification and assignment of common anatomical structures in superficial white matter. <i>NeuroImage</i> , 2008 , 43, 447-57	7.9	378
281	Revealing modular architecture of human brain structural networks by using cortical thickness from MRI. <i>Cerebral Cortex</i> , 2008 , 18, 2374-81	5.1	356
280	Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants. <i>NeuroImage</i> , 2009 , 46, 486-99	7.9	354
279	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , 2020 , 19, 422-433	24.1	286
278	Multi-level bootstrap analysis of stable clusters in resting-state fMRI. <i>NeuroImage</i> , 2010 , 51, 1126-39	7.9	237
277	Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. <i>Journal of Neuroscience</i> , 2008 , 28, 9287-96	6.6	227
276	Atlas-guided tract reconstruction for automated and comprehensive examination of the white matter anatomy. <i>NeuroImage</i> , 2010 , 52, 1289-301	7.9	226
275	Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 25	9	213
274	[F]FDG PET signal is driven by astroglial glutamate transport. <i>Nature Neuroscience</i> , 2017 , 20, 393-395	25.5	144
273	Age-related alterations in the modular organization of structural cortical network by using cortical thickness from MRI. <i>NeuroImage</i> , 2011 , 56, 235-45	7.9	130
272	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
271	Early-onset familial Alzheimer's disease (EOFAD). <i>Canadian Journal of Neurological Sciences</i> , 2012 , 39, 436-45	1	126
270	Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. <i>Journal of Neuroscience</i> , 2012 , 32, 4705-15	6.6	125
269	Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. <i>NeuroImage</i> , 2005 , 25, 868-76	7.9	110
268	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2019 , 25, 77-95	11.5	108
267	Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. <i>Neurobiology of Disease</i> , 2014 , 68, 126-36	7.5	105

266	alpha-[11C]Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. <i>European Neuropsychopharmacology</i> , 2006 , 16, 220-3	1.2	100
265	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDT4). <i>Canadian Geriatrics Journal</i> , 2012 , 15, 120-6	2.8	98
264	Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. <i>Archives of General Psychiatry</i> , 2004 , 61, 556-63		98
263	Amyloid- β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2017 , 22, 306-311	15.1	86
262	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021 , 141, 709-724	14.3	83
261	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. <i>Nature Communications</i> , 2019 , 10, 4227	17.4	77
260	Odor identification as a biomarker of preclinical AD in older adults at risk. <i>Neurology</i> , 2017 , 89, 327-335	6.5	74
259	Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. <i>Progress in Neurobiology</i> , 2013 , 110, 102-13	10.9	73
258	Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β <i>JAMA Neurology</i> , 2020 , 77, 470-479	17.2	71
257	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021 , 26, 429-442	15.1	70
256	In vivo quantification of neurofibrillary tangles with [F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 74	9	69
255	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. <i>Journal of Neuroinflammation</i> , 2014 , 11, 120	10.1	66
254	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020 , 143, 2818-2830	11.2	65
253	Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [F]-FEOBV. <i>Molecular Psychiatry</i> , 2017 , 22, 1531-1538	15.1	62
252	Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid- β and cerebrovascular pathology. <i>PLoS ONE</i> , 2013 , 8, e68612	3.7	62
251	Identifying incipient dementia individuals using machine learning and amyloid imaging. <i>Neurobiology of Aging</i> , 2017 , 59, 80-90	5.6	61
250	Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. <i>NeuroImage</i> , 2003 , 19, 1127-36	7.9	61
249	Mild behavioral impairment is associated with β amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020 , 16, 192-199	1.2	60

248	Synergistic interaction between amyloid and tau predicts the progression to dementia. <i>Alzheimers and Dementia</i> , 2017 , 13, 644-653	1.2	57
247	In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010 , 30, 1538-49	7.3	51
246	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
245	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimers and Dementia</i> , 2019 , 15, 742-753	1.2	50
244	Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. <i>Epilepsia</i> , 2001 , 42, 1124-9	6.4	50
243	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017 , 88, 1814-1821	6.5	49
242	Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study. <i>NeuroImage</i> , 2014 , 98, 195-202	7.9	48
241	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimers and Dementia</i> , 2020 , 16, 1182-1195	1.2	48
240	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimers and Dementia</i> , 2021 , 17, 1145-1156	1.2	48
239	INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. <i>Neurology</i> , 2019 , 92, e2070-e2080	6.5	47
238	Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. <i>NeuroImage</i> , 2006 , 30, 26-35	7.9	46
237	Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. <i>American Journal of Pathology</i> , 2010 , 177, 3071-80	5.8	45
236	Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. <i>International Review of Neurobiology</i> , 2005 , 63, 1-20	4.4	45
235	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. <i>Frontiers in Neuroinformatics</i> , 2016 , 10, 20	3.9	44
234	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021 , 27, 1592-1599	30.5	44
233	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. <i>IEEE Transactions on Medical Imaging</i> , 2017 , 36, 1758-1768	11.7	43
232	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018 , 90, e932-e939	6.5	41
231	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. <i>NeuroImage</i> , 2010 , 49, 1406-15	7.9	41

230	Developments in Tau PET Imaging. <i>Canadian Journal of Neurological Sciences</i> , 2014 , 41, 547-53	1	40
229	Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. <i>PLoS ONE</i> , 2012 , 7, e47905	3.7	40
228	Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 11603-11608	11.5	40
227	Aβ-induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019 , 10, 2353	17.4	39
226	Distinct increased metabotropic glutamate receptor type 5 (mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. <i>Hippocampus</i> , 2013 , 23, 1212-30	3.5	37
225	[18F]SiFA-isothiocyanate: a new highly effective radioactive labeling agent for lysine-containing proteins. <i>ChemBioChem</i> , 2009 , 10, 1321-4	3.8	37
224	Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 152-162	8.8	35
223	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. <i>Synapse</i> , 2004 , 53, 222-33	2.4	34
222	Intact memory in TGF-β transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011 , 31, 200-11	7.3	33
221	Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015 , 35, 1169-74	7.3	32
220	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <i>Trends in Neurosciences</i> , 2014 , 37, 629-41	13.3	32
219	Superficially located white matter structures commonly seen in the human and the macaque brain with diffusion tensor imaging. <i>Brain Connectivity</i> , 2011 , 1, 37-47	2.7	31
218	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018 , 3, 463-472	3.4	30
217	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 80	9	30
216	Test-retest stability of cerebral mGluR5 quantification using [(11)C]ABP688 and positron emission tomography in rats. <i>Synapse</i> , 2012 , 66, 552-60	2.4	30
215	Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. <i>NeuroImage</i> , 2007 , 35, 38-46	7.9	30
214	Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 1589-1600	4.3	28
213	Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress. <i>Brain Structure and Function</i> , 2018 , 223, 3711-3729	4	28

212	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. <i>Journal of Neuroscience</i> , 2017 , 37, 12263-12271	6.6	28
211	PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). <i>NeuroImage</i> , 2012 , 62, 555-61	7.9	28
210	Cholinergic Depletion in Alzheimer's Disease Shown by [(18) F]FEOBV Autoradiography. <i>International Journal of Molecular Imaging</i> , 2013 , 2013, 205045		28
209	Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2018 , 7, 23	10.3	28
208	Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. <i>Brain Research Bulletin</i> , 2012 , 87, 406-12	3.9	27
207	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020 , 40, 1576-1585	7.3	26
206	In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. <i>Brain Structure and Function</i> , 2016 , 221, 1387-402	4	26
205	Identification of [F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 1737-1743	8.3	25
204	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004 , 22, 1076-83	7.9	25
203	Deficit in sustained attention following selective cholinergic lesion of the pedunculo-pontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [18F]fluoroethoxybenzovesamicol. <i>Behavioural Brain Research</i> , 2015 , 278, 107-14	3.4	24
202	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. <i>Neurotherapeutics</i> , 2019 , 16, 600-610	6.4	24
201	Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease. <i>Scientific Data</i> , 2015 , 2, 150043	8.2	24
200	Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: a combined alpha-[11C]MT and [18F]MPPF positron emission tomography study. <i>NeuroImage</i> , 2008 , 42, 850-7	7.9	24
199	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019 , 77, 169-177	5.6	24
198	Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. <i>Human Brain Mapping</i> , 2018 , 39, 971-984	5.9	24
197	APOE ϵ 4 potentiates the relationship between amyloid- β and tau pathologies. <i>Molecular Psychiatry</i> , 2020 ,	15.1	23
196	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014 , 21, 143-8	2.7	23
195	Resting state executive control network adaptations in amnesic mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 993-1004	4.3	23

194	White matter abnormalities and structural hippocampal disconnections in amnesic mild cognitive impairment and Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e74776	3.7	23
193	Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , 2021 ,	6.5	23
192	Machine Learning in Nuclear Medicine: Part 1-Introduction. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 451-458	5.9	22
191	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. <i>Experimental Gerontology</i> , 2018 , 107, 169-177	4.5	22
190	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2016 , 43, 503-12	1	22
189	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 610-617	6	22
188	Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 577-590	4.3	21
187	In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. <i>Translational Neurodegeneration</i> , 2014 , 3, 6	10.3	21
186	Design, construction, and validation of an MRI-compatible vibrotactile stimulator intended for clinical use. <i>Journal of Neuroscience Methods</i> , 2009 , 184, 129-35	3	21
185	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016 , 10, 79-90	2.1	21
184	Aβ4 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019 , 10, 2240	17.4	20
183	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1021-1030	8.8	20
182	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, S3	9	20
181	Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-[(N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 7816-23	3.4	20
180	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020 , 143, 3793-3804	11.2	20
179	Determining Amyloid-Positivity Using F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 247-252	8.9	20
178	Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents. <i>ACS Chemical Neuroscience</i> , 2015 , 6, 260-76	5.7	19
177	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2012 , 39, S1-8	1	19

176	Intermediate flortaucipir uptake is associated with AβPET and CSF tau in asymptomatic adults. <i>Neurology</i> , 2020 , 94, e1190-e1200	6.5	18
175	Common Effects of Amnesic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies. <i>Frontiers in Aging Neuroscience</i> , 2015 , 7, 242	5.3	18
174	MDMA-evoked changes in cerebral blood flow in living porcine brain: correlation with hyperthermia. <i>Synapse</i> , 2004 , 53, 214-21	2.4	18
173	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021 , 78, 1471-1483	17.2	18
172	Association of Vascular Risk Factors With βAmyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. <i>JAMA Network Open</i> , 2020 , 3, e1920780	10.4	17
171	Impact of scale space search on age- and gender-related changes in MRI-based cortical morphometry. <i>Human Brain Mapping</i> , 2013 , 34, 2113-28	5.9	17
170	Prevention strategies for Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2012 , 1, 13	10.3	17
169	Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018 , 75, 608-619	17.2	16
168	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. <i>MedChemComm</i> , 2015 , 6, 2184-2193	5	16
167	PET imaging with [¹⁸ F]fluoroethoxybenzovesamicol ([¹⁸ F]FEOBV) following selective lesion of cholinergic pedunculo-pontine tegmental neurons in rat. <i>Nuclear Medicine and Biology</i> , 2014 , 41, 96-101	2.1	16
166	Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults. <i>Frontiers in Neuroscience</i> , 2019 , 13, 22	5.1	15
165	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. <i>Molecular Diagnosis and Therapy</i> , 2011 , 15, 313-25	4.5	15
164	Brain regional alpha-[¹¹ C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis, in healthy adults: absence of an age effect. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 1254-64	8.8	15
163	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [¹¹ C]ABP688 Positron-Emission Tomography (PET) Imaging. <i>Cerebral Cortex</i> , 2016 , 26, 4170-4179	5.1	15
162	Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. <i>Frontiers in Neuroscience</i> , 2019 , 13, 875	5.1	14
161	Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. <i>Alzheimer's and Dementia</i> , 2019 , 15, 951-960	1.2	14
160	Morphometric network differences in ageing versus Alzheimer's disease dementia. <i>Brain</i> , 2020 , 143, 635-649	11.2	14
159	Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. <i>Translational Neurodegeneration</i> , 2018 , 7, 12	10.3	14

158	Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, S4	9	14
157	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, S8	9	14
156	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 6897-6910	8.3	14
155	Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking. <i>Frontiers in Human Neuroscience</i> , 2017 , 11, 128	3.3	14
154	MicroPET imaging of 5-HT 1A receptors in rat brain: a test-retest [18F]MPPF study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 53-62	8.8	14
153	Is ApoE e 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. <i>Translational Neurodegeneration</i> , 2016 , 5, 20	10.3	14
152	Regional Amyloid-Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. <i>Molecular Neurobiology</i> , 2019 , 56, 4916-4924	6.2	14
151	PET imaging of freely moving interacting rats. <i>NeuroImage</i> , 2019 , 191, 560-567	7.9	13
150	Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 70, 747-756	4.3	13
149	Stability of alpha-[11C]methyl-L-tryptophan brain trapping in healthy male volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 1199-204	8.8	13
148	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 776-785	7.9	13
147	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 859-869	4.3	13
146	Test-retest variability of [C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans. <i>Synapse</i> , 2018 , 72, e22041	2.4	13
145	The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 107-113	6	12
144	Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry. <i>EJNMMI Research</i> , 2013 , 3, 70	3.6	12
143	Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , 2009 , 30, 1328-37	5.9	12
142	TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. <i>Biochemical Pharmacology</i> , 2010 , 80, 1572-9	6	12
141	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020 , 49, 334-348	2.6	12

140	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019 , 24, 102091	5.3	12
139	The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. <i>Sleep Medicine Reviews</i> , 2021 , 55, 101384	10.2	12
138	Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 551-558	4.3	11
137	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. <i>Translational Psychiatry</i> , 2021 , 11, 251	8.6	11
136	A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2295-2305	8.8	11
135	In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy. <i>Annals of Neurology</i> , 2019 , 85, 218-228	9.4	11
134	Constrained instruments and their application to Mendelian randomization with pleiotropy. <i>Genetic Epidemiology</i> , 2019 , 43, 373-401	2.6	11
133	PET/CT of Dementia. <i>American Journal of Roentgenology</i> , 2018 , 211, 246-259	5.4	11
132	Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer. <i>Journal of Prevention of Alzheimer's Disease</i> , 2016 , 3, 164-172	3.8	10
131	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 69	9	10
130	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1398	5.6	10
129	Topographic Distribution of Amyloid- β , Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e81-e92	6.5	10
128	First-in-Human Brain Imaging of [F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 2697-2702	5.7	9
127	Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke. <i>Neurorehabilitation and Neural Repair</i> , 2016 , 30, 941-950	4.7	9
126	Motion compensation for fully 4D PET reconstruction using PET superset data. <i>Physics in Medicine and Biology</i> , 2010 , 55, 4063-82	3.8	9
125	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021 , 16, 28	19	9
124	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2020 ,	15.1	8
123	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S23-S31	4.3	8

122	Epistasis analysis links immune cascades and cerebral amyloidosis. <i>Journal of Neuroinflammation</i> , 2015 , 12, 227	10.1	8
121	Time-efficient and convenient synthesis of [(18)F]altanserin for human PET imaging by a new work-up procedure. <i>Applied Radiation and Isotopes</i> , 2009 , 67, 2040-3	1.7	8
120	Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 1331-1350	2.3	7
119	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, β , and Cognitive Impairment. <i>Neurology</i> , 2021 , 96, e975-e985	6.5	7
118	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021 , 3, fcab073	4.5	7
117	A simplified radiosynthesis of [F]MK-6240 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019 , 62, 109-114	1.9	7
116	Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021 , 31, 102733	5.3	7
115	Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016 , 36, 2211-2222	7.3	6
114	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. <i>Pharmaceuticals</i> , 2019 , 12,	5.2	6
113	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021 ,	11.2	6
112	variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , 2018 , 4, e216	3.8	5
111	Open Science Datasets from PREVENT-AD, a Longitudinal Cohort of Pre-symptomatic Alzheimer's Disease		5
110	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021 , 10, 1	10.3	5
109	Cholinergic Modulation of Binocular Vision. <i>Journal of Neuroscience</i> , 2020 , 40, 5208-5213	6.6	4
108	Topographical distribution of A β predicts progression to dementia in A β -positive mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12037	5.2	4
107	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 12-21	5.2	4
106	Motion-compensated fully 4D PET reconstruction using PET data supersets 2009 ,		4
105	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.. <i>EBioMedicine</i> , 2022 , 76, 103836	8.8	4

104	Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling. <i>TeMa</i> , 2017 , 18, 15	0.8	4
103	Mapping neurotransmitter systems to the structural and functional organization of the human neocortex		4
102	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. <i>Nature Reviews Neurology</i> , 2022 ,	15	4
101	Towards the PET radiotracer for p75 neurotrophin receptor: [(11)C]LM11A-24 shows biological activity in vitro, but unfavorable ex vivo and in vivo profile. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 4759-4765	3.4	3
100	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. <i>Neurodegenerative Diseases</i> , 2014 , 13, 197-9	2.3	3
99	Mapping neurotransmitter systems to the structural and functional organization of the human neocortex		3
98	Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016 , 22, 615-8	3	3
97	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , 2020 , 33, 288-293	1.6	3
96	Interactive rather than independent effect of and sex potentiates tau deposition in women. <i>Brain Communications</i> , 2021 , 3, fcab126	4.5	3
95	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021 , 3, fcab136	4.5	3
94	Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 22-29	8.9	3
93	Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. <i>Journal of Psychiatry and Neuroscience</i> , 2021 , 46, E1-E13	4.5	3
92	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021 , 10, 11	10.3	3
91	Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [F]-FEOBV. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 162-166	3.6	3
90	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease.. <i>Neuropsychopharmacology</i> , 2022 ,	8.7	3
89	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum. <i>Molecular Neurobiology</i> , 2019 , 56, 8336-8344	6.2	2
88	No apparent effect of naproxen on CSF markers of innate immune activation. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1127-1133	5.3	2
87	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. <i>Future Neurology</i> , 2014 , 9, 597-613	1.5	2

86	Dementia: Disclosure of results to participants in dementia research. <i>Nature Reviews Neurology</i> , 2013 , 9, 608-9	15	2
85	Clozapine induces astrocyte-dependent FDG-PET hypometabolism.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	2
84	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 ,	5.9	2
83	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	2
82	Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views. <i>Current Neurology and Neuroscience Reports</i> , 2021 , 21, 52	6.6	2
81	Dynamic H-MRS for detection of C-labeled glucose metabolism in the human brain at 3T. <i>Magnetic Resonance in Medicine</i> , 2020 , 84, 1140-1151	4.4	2
80	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> ,		2
79	Le diagnostic précoce de la maladie d'Alzheimer : panacée ou catastrophe ?. <i>Ethics, Medicine and Public Health</i> , 2015 , 1, 151-154	0.7	1
78	PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1438	5.1	1
77	Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018 , 141, e68	11.2	1
76	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. <i>Translational Neuroscience</i> , 2014 , 5,	1.2	1
75	IC-P-012: Should a global or a regional measure of amyloidosis be used in a longitudinal study? 2015 , 11, P19-P19		1
74	Development of fMRI techniques for planning in functional neurosurgery for Parkinson's disease 2008 ,		1
73	Dosimetry of PET tracers in mice using microPET scans as an input function		1
72	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET.. <i>EBioMedicine</i> , 2022 , 76, 103837	8.8	1
71	Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12085	6	1
70	18F-MK-6240 tau-PET in genetic frontotemporal dementia. <i>Brain</i> , 2021 ,	11.2	1
69	Amyloid-dependent and amyloid-independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 2083-2092	5.3	1

68	Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer's disease		1
67	Impact of long- and short-range fiber depletion on the cognitive deficits of fronto-temporal dementia		1
66	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative		1
65	Efficient radiosynthesis and preclinical evaluation of [¹⁸ F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020 , 63, 144-150	1.9	1
64	CCCDT5: research diagnostic criteria for Alzheimer's Disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12036	6	1
63	Stable brain PET metabolic networks using a multiple sampling scheme		1
62	Artificial intelligence for molecular neuroimaging. <i>Annals of Translational Medicine</i> , 2021 , 9, 822	3.2	1
61	A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment. <i>Data in Brief</i> , 2016 , 9, 1122-1129	1.2	1
60	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020 , 35, 60-68	3.9	1
59	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12154	6	1
58	Preclinical longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 271678X211035625	7.3	1
57	The calcium sensor synaptotagmin-1 is critical for phasic axonal dopamine release in the striatum and mesencephalon, but is dispensable for basic motor behaviors in mice		1
56	Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology.. <i>Cell and Bioscience</i> , 2021 , 11, 204	9.8	0
55	CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12098 ⁶		0
54	Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset. <i>Neuroscience</i> , 2021 , 480, 143-154	3.9	0
53	In vivo hippocampal cornu ammonis 1-3 glutamatergic abnormalities are associated with temporal lobe epilepsy surgery outcomes. <i>Epilepsia</i> , 2021 , 62, 1559-1568	6.4	0
52	Phantom bedside intruder in Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2019 , 7, 91-93	0.3	0
51	Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. <i>NeuroImage: Clinical</i> , 2021 , 29, 102552	5.3	0

50	FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. <i>Journal of Neuroimaging</i> , 2021 , 31, 1077-1081	2.8	o
49	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, β , and Cognitive Impairment.. <i>Neurology</i> , 2021 , 97, 609	6.5	o
48	Preliminary Evaluations of [C]Verubulin: Implications for Microtubule Imaging With PET. <i>Frontiers in Neuroscience</i> , 2021 , 15, 725873	5.1	o
47	Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017 , 89, 1931	6.5	
46	Neuroinflammation imposes vulnerability to tau propagation. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039814		
45	P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline 2016 , 12, P627-P628		
44	IC-P-176: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNO-RESPONSE 2014 , 10, P98-P99		
43	P1-049: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNORESPONSE 2014 , 10, P321-P321		
42	P3-133: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study 2015 , 11, P674-P675		
41	P4-097: Should a global or a regional measure of amyloidosis be used in a longitudinal study? 2015 , 11, P811-P811		
40	[P4B06]: COMPARISON BETWEEN MONOAMINE OXIDASE B INHIBITION ON THE UPTAKE OF [18F]THK5351 2017 , 13, P1533-P1534		
39	[P4B66]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS 2017 , 13, P1569		
38	[O21402]: PRECLINICAL ASSESSMENT OF KAL-ABP TARGET ENGAGEMENT AND EFFICACY USING PET, MRI AND CSF BIOMARKERS 2017 , 13, P591-P592		
37	FTS-04-03: Clinical utility of amyloid PET in the differential diagnosis of atypical dementias and its impact on caregivers 2015 , 11, P264-P264		
36	IC-P-011: Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates 2015 , 11, P18-P19		
35	IC-P-027: Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP RAT 2015 , 11, P27-P28		
34	IC-P-026: Amyloidosis induces reorganization of the hippocampal metabolic network 2015 , 11, P27-P27		
33	P1-036: Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP rat 2015 , 11, P350-P351		

32	P3-180: Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates 2015 , 11, P699-P699	
31	IC-P-155: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects 2015 , 11, P104-P104	
30	P1-159: Amyloidosis induces reorganization of the hippocampal metabolic network 2015 , 11, P405-P406	
29	P1-177: Extensive white matter burden represents a new radiological phenotype in a distinct population of ad patients 2015 , 11, P412-P413	
28	O5-01-06: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects 2015 , 11, P314-P315	
27	Diagnosis of Alzheimer's disease 2012 , 12-46	
26	Introduction to the diagnosis of dementia1-5	
25	Young man with slow cognitive decline277-281	
24	4e Conférence canadienne consensuelle sur le diagnostic et le traitement de la démence. <i>Canadian Journal of Neurological Sciences</i> , 2012 , 39, S1-S8	1
23	Accelerated microPET Transmission Imaging. <i>IEEE Transactions on Nuclear Science</i> , 2008 , 55, 2501-2507	1.7
22	Radiosynthesis of cis-4-[124I]iodo-L-proline as a prototype probe for imaging anterograde axoplasmic transport systems using positron emission tomography (PET). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2007 , 50, 636-637	1.9
21	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004 , 22, 1076-1076	7.9
20	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. <i>NeuroMethods</i> , 2018 , 235-248	0.4
19	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , 2016 , 1-13	0.1
18	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , 2017 , 141-153	0.1
17	Advances in Alzheimer's disease management 2012 , 2-3	
16	Elderly Man Repeating Questions about Upcoming Appointments 2021 , 14-17	
15	IC-P-027: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline 2016 , 12, P28-P29	

- 14 IC-P-025: [18F]Florbetapir Roc Curve at Every Voxel Revels a Wide Range of Cortical Suvr Cut-Offs **2016**, 12, P27-P28
- 13 P1-251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Cortical-Subcortical Circuits Causes Memory Declines in Animal Models **2016**, 12, P504-P505
- 12 P1-282: Voxel-Wise Logistic Regression Improves Prediction Accuracy for Developing Alzheimer's Disease **2016**, 12, P527-P527
- 11 IC-P-086: Amyloid- β and Hyperphosphorylated TAU Synergy Drives Clinical Progression to Alzheimer's Disease **2016**, 12, P66-P67
- 10 IC-P-099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Cortical-Subcortical Circuits Causes Memory Declines in Animal Models **2016**, 12, P75-P76
- 9 P2-093: Polymorphism in Cytochrome P450 Gene is Associated with Alzheimer's Pathology **2016**, 12, P646-P646
- 8 IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model **2016**, 12, P77-P77
- 7 IC-P-157: Novel Toolbox for Performing Voxel-Wise Generalized Linear Regression With Multiple Volumetric Covariates in Longitudinal Data **2016**, 12, P116-P117
- 6 P3-221: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model **2016**, 12, P910-P910
- 5 IC-P-159: Voxel-Wise Logistic Regression Improves Prediction Accuracy for Developing AD **2016**, 12, P117-P118
- 4 P3-251: Novel Toolbox for Performing Voxel-Wise Generalized Linear Regression with Multiple Volumetric Covariates in Longitudinal Data **2016**, 12, P925-P926
- 3 O5-02-06: The Association between white Matter Hyperintensities and Memory Impairment Depends on P-TAU Levels in a High-Risk Cohort of Aging Cognitively Normal Persons **2016**, 12, P381-P381
- 2 P4-310: The Effect of Lumbar Puncture on the Retention of the Prevent-ad Cohort ad **2016**, 12, P1152-P1152
- 1 Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada. *Canadian Journal of Neurological Sciences*, **2021**, 48, 312-320 1